Nicole Sander, Dora Stölzl, Melina Fonfara, Jan Hartmann, Inken Harder, Ina Suhrkamp, Ivone Jakaša, Ellen van den Bogaard, Ivonne van Vlijmen-Willems, Silke Szymczak, Elke Rodriguez, Sascha Gerdes, Stephan Weidinger
BACKGROUND: Interleukin (IL)-13 is a key driver of inflammation and barrier dysfunction in atopic dermatitis (AD). While there is robust evidence that tralokinumab, a monoclonal antibody neutralizing IL-13, reduces inflammation and clinical disease activity, less is known about its effects on barrier function. OBJECTIVES: To characterize effects of tralokinumab treatment on skin barrier function. METHODS: Transepidermal water loss (TEWL), stratum corneum hydration (SCH), natural moisturizing factor (NMF) content, histopathological characteristics, biomarker expression and microbiome composition were evaluated in lesional, non-lesional, and sodium lauryl sulfate (SLS)-irritated skin of 16 AD patients over the course of 16 weeks of tralokinumab treatment...
March 26, 2024: British Journal of Dermatology